Li Yi, Li Dong-hong, Yao Yuan-qing, Min Bao-hua, Zhang Chun-li, Hou Xiu-hong, Huang Liang, Zhao Hong-xi
Department of Obstetrics and Gynecology, Tangdu hospital, Fourth Military Medical University, Xi'an 710038, China.
Zhonghua Fu Chan Ke Za Zhi. 2005 Sep;40(9):581-4.
To investigate the alteration of serum soluble fms-like tyrosine kinase receptor 1 (sFlt-1) and the possible source in preeclampsia, and the relationship between sFlt-1 and the pathogenesis of preeclampsia.
(1) Semi-quantitative RT-PCR was carried out to detect the level of sFlt-1 mRNA in placental tissue of 10 preeclampsia (preeclampsia group) and 10 normotensive pregnancies (normotensive pregnancy group). (2) Enzyme linked immunosorbent assay (ELISA) was used to detect the serum level of sFlt-1 in peripheral venous blood in preeclampsia group 1 (n = 35) and normotensive pregnancies group 1 (n = 35); the serum level of sFlt-1 of uterine vein blood in preeclampsia group 2 (n = 20) and normotensive pregnancies group 2 (n = 20); and the volume of peripheral venous blood sFlt-1 in 10 early (early pregnancy group) and 10 middle pregnancies (middle pregnancy group).
(1) sFlt-1 mRNA of placental tissue was significantly higher in preeclampsia group (0.95 +/- 0.04) than that in normal pregnancy group (0.64 +/- 0.15). (2) The serum level of sFlt-1 of peripheral vein in preeclampsia group 1 (5640 +/- 3191) ng/L was higher than that in normal pregnancy group 1 (2194 +/- 635) ng/L. (3) The serum sFlt-1 of uterine vein in preeclampsia group 2 (7673 +/- 2296) ng/L was higher than that in normotensive pregnancy group 2 (3057 +/- 785) ng/L, indicating that the volume of sFlt-1 of uterine vein blood was significantly higher than that of peripheral venous blood (P < 0.01). (4) The serum levels of sFlt-1 in early and middle pregnancy groups were (32 +/- 20) ng/L and (994 +/- 302) ng/L, respectively, showing that the level of sFlt-1 in peripheral venous blood increasingly elevated with the development of pregnancy.
(1) The placenta may be the major source of elevated sFlt-1. (2) The serum level of sFlt-1 is related with the development of pregnancy. The alteration of sFlt-1 may contribute to the pathogenesis of preeclampsia.
探讨子痫前期患者血清可溶性fms样酪氨酸激酶受体1（sFlt-1）的变化及其可能来源，以及sFlt-1与子痫前期发病机制的关系。
（1）采用半定量逆转录聚合酶链反应（RT-PCR）检测10例子痫前期患者（子痫前期组）和10例血压正常孕妇（正常妊娠组）胎盘组织中sFlt-1 mRNA水平。（2）采用酶联免疫吸附测定（ELISA）法检测子痫前期组1（n = 35）和正常妊娠组1（n = 35）外周静脉血中sFlt-1的血清水平；子痫前期组2（n = 20）和正常妊娠组2（n = 20）子宫静脉血中sFlt-1的血清水平；以及10例早孕（早孕组）和10例中孕（中孕组）外周静脉血中sFlt-1的含量。
（1）子痫前期组胎盘组织sFlt-1 mRNA水平（0.95±0.04）显著高于正常妊娠组（0.64±0.15）。（2）子痫前期组1外周静脉血sFlt-1血清水平（5640±3191）ng/L高于正常妊娠组1（2194±635）ng/L。（3）子痫前期组2子宫静脉血sFlt-1血清水平（7673±2296）ng/L高于正常妊娠组2（3057±785）ng/L，表明子宫静脉血中sFlt-1含量显著高于外周静脉血（P < 0.01）。（4）早孕组和中孕组外周静脉血sFlt-1血清水平分别为（32±20）ng/L和（994±302）ng/L，表明外周静脉血中sFlt-1水平随孕周增加而升高。
（1）胎盘可能是sFlt-1升高的主要来源。（2）血清sFlt-1水平与妊娠进展有关。sFlt-1的变化可能参与子痫前期的发病机制。
Zotero 插件